Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 5/20 | 0.39 |
| ▸ | MAOB | P27338 | 4/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | DRD2 | P14416 | 1/20 | 0.35 |
| ▸ | DRD1 | P21728 | 1/20 | 0.35 |
| ▸ | DRD4 | P21917 | 1/20 | 0.35 |
| ▸ | DRD5 | P21918 | 1/20 | 0.35 |
| ▸ | DRD3 | P35462 | 1/20 | 0.35 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25101118 | 0.87 | MAOA (0.39) | MAOAMAOBSLC6A4L3MBTL1DRD2 | |
| SCHEMBL29310054 | 0.82 | CYP2D6 (0.40) | MAOAMAOBSLC6A4CYP1A2CYP2D6 | |
| SCHEMBL22859078 | 0.79 | MAOA (0.41) | MAOAMAOBSLC6A4CYP1A2CYP2D6 | |
| SCHEMBL29310399 | 0.79 | NMT1 (0.34) | DRD2DRD1DRD5DRD3 | |
| SCHEMBL18902623 | 0.76 | MAOA (0.41) | MAOAMAOBSLC6A4CYP1A2CYP2D6 | |
| SCHEMBL29310333 | 0.76 | MAOA (0.41) | MAOAMAOBSLC6A4CYP1A2CYP2D6 | |
| SCHEMBL23735928 | 0.76 | DRD2 (0.47) | MAOAMAOBSLC6A4DRD2DRD1 | |
| SCHEMBL1619374 | 0.74 | MAOA (0.52) | MAOAMAOBSLC6A4DRD2DRD1 | |
| SCHEMBL17815391 | 0.73 | DRD1 (0.51) | MAOAMAOBSLC6A4CYP1A2CYP2D6 | |
| SCHEMBL26227089 | 0.73 | DRD1 (0.47) | MAOAMAOBSLC6A4DRD2DRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240228459-A1 | WEE1 INHIBITORS AND USES THEREOF | BOUNDLESS BIO, INC. | 2024-07-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240228459-A1 | WEE1 INHIBITORS AND USES THEREOF | WEE1, WEE2, DCLRE1B | MAOA 4159/4885MAOB 3948/4885SLC6A4 4697/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.